What is Koios Care?
Koios Care operates at the intersection of medical device manufacturing and artificial intelligence. The company specializes in the development of validated digital daily activity biomarkers, which serve as objective metrics for tracking disease progression. By integrating these sophisticated sensing capabilities into the daily lives of patients, Koios Care seeks to enhance the quality of care while simultaneously reducing the economic burden on healthcare systems. Their market position is defined by a commitment to evidence-based innovation, ensuring that their technological solutions meet the rigorous standards required for clinical adoption in the neurology space.
The company's trajectory reflects a transition from early-stage research to a more robust, enterprise-level operational model. By focusing on Parkinson’s Disease, Koios Care addresses a high-need segment of the population, utilizing data-driven insights to provide clinicians with actionable information that was previously difficult to capture in non-clinical settings.
How much funding has Koios Care raised?
Koios Care has raised a total of $1.6M across 2 funding rounds:
Other Financing Round
$380K
Other Financing Round
$1.2M
Other Financing Round (2023): $380K with participation from Lumiares
Other Financing Round (2025): $1.2M led by Ever-Curious Geek and Imec.istart
Key Investors in Koios Care
Ever-Curious Geek
A multifaceted content platform founded by Mark David Zahn that explores diverse themes including maker life and pop culture, now diversifying into strategic technology investments.
Imec.istart
A prominent accelerator and investment entity that specializes in the internationalization of tech start-ups, providing critical network access and market entry support.
Lumiares
An investment entity participating in the early-stage financing of Koios Care to support the development of innovative medical sensing technologies.
What's next for Koios Care?
With the infusion of $1.2M, Koios Care is well-positioned to accelerate its product development roadmap and expand its clinical validation efforts. The strategic focus will likely shift toward scaling its AI-driven platform to support broader diagnostic applications and potentially entering new international markets. As the company matures, the emphasis will remain on securing regulatory approvals and fostering partnerships with healthcare providers to integrate their biomarker technology into standard care protocols. This capital infusion provides the necessary runway to refine their sensing algorithms and solidify their footprint as a leader in the digital neurology sector, ultimately aiming to transform the standard of care for neurodegenerative conditions globally.
See full Koios Care company page
